CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
High Dose Drug Device +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01016691
NCT01016691Phase 2Completed

Safety and Efficacy of a Drug Delivery System in Glaucoma

Vistakon Pharmaceuticals·interventional·Posted Nov 19, 2009·Updated Mar 6, 2015

In Brief

A Phase 2 clinical trial evaluating High Dose Drug Device, Low Dose Drug Device, and 2 other interventions for Open-angle Glaucoma and Ocular Hypertension. Completed, enrolled 47 participants across 5 sites.

Detailed Summary

Evaluation of the ocular safety and efficacy of a drug delivery system in open-angle glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 19, 2009
Enrollment StartOct 1, 2009
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.6 years ago

Interventions

High Dose Drug Devicedrug

device inserted for 4 days

Low Dose Drug Devicedrug

device inserted for 4 days

Placebo Devicedrug

device inserted for 4 days

bimatoprost 0.03%drug

one drop in each eye on one day only